JP2006525786A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525786A5
JP2006525786A5 JP2004563747A JP2004563747A JP2006525786A5 JP 2006525786 A5 JP2006525786 A5 JP 2006525786A5 JP 2004563747 A JP2004563747 A JP 2004563747A JP 2004563747 A JP2004563747 A JP 2004563747A JP 2006525786 A5 JP2006525786 A5 JP 2006525786A5
Authority
JP
Japan
Prior art keywords
seq
btl
amino acids
protein
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004563747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525786A (ja
JP4671694B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/040338 external-priority patent/WO2004058986A2/en
Publication of JP2006525786A publication Critical patent/JP2006525786A/ja
Publication of JP2006525786A5 publication Critical patent/JP2006525786A5/ja
Application granted granted Critical
Publication of JP4671694B2 publication Critical patent/JP4671694B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004563747A 2002-12-23 2003-12-19 Ｂｔｌ−ｉｉ核酸、タンパク質および抗体 Expired - Fee Related JP4671694B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43618502P 2002-12-23 2002-12-23
US52529803P 2003-11-26 2003-11-26
PCT/US2003/040338 WO2004058986A2 (en) 2002-12-23 2003-12-19 Btl-ii nucleic acids, proteins, and antibodies

Publications (3)

Publication Number Publication Date
JP2006525786A JP2006525786A (ja) 2006-11-16
JP2006525786A5 true JP2006525786A5 (enExample) 2007-01-25
JP4671694B2 JP4671694B2 (ja) 2011-04-20

Family

ID=32685440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004563747A Expired - Fee Related JP4671694B2 (ja) 2002-12-23 2003-12-19 Ｂｔｌ−ｉｉ核酸、タンパク質および抗体

Country Status (9)

Country Link
US (4) US7244822B2 (enExample)
EP (1) EP1585760B1 (enExample)
JP (1) JP4671694B2 (enExample)
AU (1) AU2003299687B2 (enExample)
CA (1) CA2509999A1 (enExample)
ES (1) ES2391949T3 (enExample)
MX (1) MXPA05006535A (enExample)
PL (2) PL379564A1 (enExample)
WO (1) WO2004058986A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127418A1 (en) * 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
US20150166630A1 (en) 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
JP5830048B2 (ja) * 2013-03-15 2015-12-09 信越化学工業株式会社 チタン含有レジスト下層膜形成用組成物及びパターン形成方法
WO2019028336A1 (en) * 2017-08-03 2019-02-07 The Cleveland Clinic Foundation IMPROVED PEPTIDE EXPRESSION AND ANTIBODY DETECTION OF APO-H SPECIFIC SUBJECT
EP3759125A4 (en) * 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. METHOD OF CANCER TREATMENT USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNCHECKPOINT BLOCKING REAGENTS
IL309799A (en) * 2021-07-20 2024-02-01 Regeneron Pharma Butyrophilin-2-like substances for the treatment of inflammatory disorders
CN114437234A (zh) * 2021-12-28 2022-05-06 四川省医学科学院·四川省人民医院 Btnl2重组蛋白及其制备方法与在制备用于治疗炎症性肠病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20020168638A1 (en) 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
DE10032529A1 (de) 2000-06-30 2002-02-07 Epigenomics Ag Diagnose von bedeutenden genetischen Parametern innerhalb des Major Histocompatibility Complex (MHC)
CA2422215A1 (en) * 2000-09-20 2002-03-28 Amgen Inc. B7-like molecules and uses thereof
CA2426540A1 (en) 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
DE60327056D1 (de) 2002-02-20 2009-05-20 Vlaams Interuniv Inst Biotech Verfahren zur kontrolle der tumorprogression und invasivität

Similar Documents

Publication Publication Date Title
JP7247226B2 (ja) 水痘・帯状疱疹ウイルスの抗原バリアントおよびその使用
JP2006515749A5 (enExample)
JP2013517783A5 (enExample)
JP2021524275A5 (enExample)
JP2013541335A5 (enExample)
JP6907229B2 (ja) ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用
JP2010166921A5 (enExample)
JP2012012402A5 (enExample)
CN109796531B (zh) 猪Delta冠状病毒N蛋白单克隆抗体及其抗原表位和应用
JP2005523681A5 (enExample)
JP2011529077A (ja) Ｃ型肝炎の治療のための組成物および方法
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
WO2019080538A1 (zh) 嵌合抗原受体、其修饰的NK细胞、编码 DNA、mRNA、表达载体、制备方法和应用
JP2002512800A5 (enExample)
JP2010538619A5 (enExample)
JP2024023268A5 (enExample)
JP6213969B2 (ja) 免疫原性ポリペプチド表層発現ビフィズス菌
CA3180251A1 (en) Cytokine conjugates
JP2010514698A5 (enExample)
CN106868025A (zh) 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法
US20230381298A1 (en) Herpesvirus polyepitope vaccines
CN113166252A (zh) 全人抗gitr抗体及其制备方法
WO2020184730A1 (ja) デングウイルスワクチン
JP5097135B2 (ja) Ｂ型肝炎ワクチンの免疫応答を促進するタンパク質およびその遺伝子
CN101402942B (zh) PolyLyse-HSP70融合蛋白膜修饰的肠癌细胞瘤苗及其制备方法